The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
Open accessAbstract
Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2), are present in most gliomas and secondary glioblastomas, but are rare in other neoplasms. IDH1/2 mutations are heterozygous, and affect a single arginine residue. Recently, IDH1 mutations were identified in 8% of acute myelogenous leukemia (AML) patients. A glioma study revealed that IDH1 mutations cause a gain-of-function, resulting in the production and accumulation of 2-hydroxyglutarate (2-HG). Genotyping of 145 AML biopsies identified 11 IDH1 R132 mutant samples. Liquid chromatography-mass spectrometry metabolite screening revealed increased 2-HG levels in IDH1 R132 mutant cells and sera, and uncovered two IDH2 R172K mutations. IDH1/2 mutations were associated with normal karyotypes. Recombinant IDH1 R132C and IDH2 R172K proteins catalyze the novel nicotinamide adenine dinucleotide phosphate (NADPH)–dependent reduction of α-ketoglutarate (α-KG) to 2-HG. The IDH1 R132C mutation commonly found in AML reduces the affinity for isocitrate, and increases the affinity for NADPH and α-KG. This prevents the oxidative decarboxylation of isocitrate to α-KG, and facilitates the conversion of α-KG to 2-HG. IDH1/2 mutations confer an enzymatic gain of function that dramatically increases 2-HG in AML. This provides an explanation for the heterozygous acquisition of these mutations during tumorigenesis. 2-HG is a tractable metabolic biomarker of mutant IDH1/2 enzyme activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The high concentrations of R-2HG (more than 10 mM) that have been observed in malignant brain tumours and leukaemias (Dang et al, 2009;Gross et al, 2010;Ward et al, 2010), might be sufficient to inhibit even the less-susceptible 2OG oxygenases.”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Gross et al, 2010
In the citing paper
“However, they also cause a gain of function comprising catalysis of 2OG to the R-enantiomer of 2-hydroxyglutarate (R-2HG; Dang et al, 2009;Gross et al, 2010;Ward et al, 2010).”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Gross et al, 2010
In the citing paper
“Tumor-associated IDH mutations unmask a latent ability of these enzymes to produce the R enantiomer of 2-hydroxyglutarate, which accumulates to low millimolar levels in IDH mutant tumors (Dang et al., 2009; Gross et al., 2010; Ward et al., 2010).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Gross et al., 2010
In the citing paper
“AML samples with low to undetectable 2HG were subsequently sequenced and determined to be IDH1 and IDH2 wild-type”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Gross et al., 2010
In the citing paper
“several samples with elevated 2HG were found to have neomorphic mutations at either IDH1 R132 or IDH2 R172 (Gross et al., 2010)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Gross et al., 2010
In the citing paper
“Enzymatic assays and measurement of 2HG levels in primary AML samples confirmed that these IDH2 R172 mutations result in 2HG elevation (Gross et al., 2010; Ward et al., 2010).”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Gross et al., 2010
In the citing paper
“serum 2HG levels have successfully correlated with IDH1 R132 mutations in AML”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Gross et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationRecurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Hartmann, C. J., Meyer, J., Balß, J., Capper, D., Mueller, W. C., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Sanson, M., Marie, Y., Paris, S., Idbaïh, A., Laffaire, J., Ducray, F., Hallani, S. E., Boisselier, B., Mokhtari, K., Hoang‐Xuan, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9832 · Cited by 1,049
Analysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas
Watanabe, T., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080958 · Cited by 1,027
Nishihara, K., Kanemori, M., Kitagawa, M., Yanagi, H., & Yura, T. (1998) · Applied and Environmental Microbiology · doi:10.1128/aem.64.5.1694-1699.1998 · Cited by 440
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 744
Novel canine isocitrate dehydrogenase 1 mutation Y208C attenuates dimerization ability
Kawakami, S., Michishita, M., Sakaue, M., Morimatsu, M., Uemura, M., Kashiwagi, N., Maeda, M., Machida, Y., Azakami, D., Egusa, A. S., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.12214 · Cited by 3
Kao, H., Kuo, M., Huang, Y., Chang, H., Hu, S.-F., Huang, C., Hung, Y., Lin, T., Ou, C., Lien, M., et al. (2022) · Cancers · doi:10.3390/cancers14246205 · Cited by 3
Ohtawa, T., & Tsunoda, M. (2023) · Analytical Methods · doi:10.1039/d3ay00263b · Cited by 3
Therapeutic approaches targeting oncogenic proteins in myeloid leukemia: challenges and perspectives
Yan, X. Y., Kang, Y. Y., Zhang, Z. Y., Huang, P. C., Yang, C., & Naranmandura, H. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2443577 · Cited by 3
Biology – cancer metabolic phenotype
Čuperlović‐Culf, M. (2013) · Elsevier eBooks · doi:10.1533/9781908818263.15 · Cited by 3
Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation
Pasquier, F., Chahine, C., Marzac, C., & de Botton, S. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1792286 · Cited by 3
Molecular Pathology and Diagnostics of Gliomas
Kresak, J. L., & Shan, Y. (2013) · Springer eBooks · doi:10.1007/978-94-007-7192-5_1 · Cited by 3
Les ROS : une nouvelle cible thérapeutique dans les leucémies ?
Callens, C., Moura, I. C., & Hermine, O. (2010) · médecine/sciences · doi:10.1051/medsci/201026121033 · Cited by 3
Bock, O. (2013) · Journal of Leukemia · doi:10.4172/2329-6917.1000108 · Cited by 3
Targeted Metabolomics: The Next Generation of Clinical Chemistry!
Weinberger, K. M., & Breit, M. (2016) · Translational bioinformatics · doi:10.1007/978-94-017-7543-4_7 · Cited by 3
Shumilov, E., Flach, J., Joncourt, R., Porret, N. A., Wiedemann, G., Novak, U., Gfeller, E., Jeker, B., Amstutz, U., Pabst, T., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1585838 · Cited by 3
IDH1 regulates human erythropoiesis by eliciting chromatin state reprogramming
Li, M., Zhang, H., Wu, X., Yu, M., Yang, Q., Sun, L., Li, W., Jiang, Z., Xue, F., Wang, T. T., et al. (2024) · eLife · doi:10.7554/elife.100406.3 · Cited by 3
Scaffold modification and synthesis routes for targeting mutant IDH 1: a review
Pai, V. S., & Kumar, N. (2025) · Discover Applied Sciences · doi:10.1007/s42452-025-07293-7 · Cited by 2
From the T-cell receptor to cancer therapy: an interview with Tak W. Mak
Mak, T. W. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-00666-y · Cited by 2
Self-citationStatus of IDH mutations in chondrosarcoma of the jaws
You, Z., Zhang, J., Zhang, H., Li, X., Sun, Z., & Sun, L. (2022) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2022.03.003 · Cited by 2
Tracing the history of clinical practice of liquid biopsy: a bibliometric analysis
Zhang, S., Zhao, H., Wang, K., Li, L., Pan, Q., Lu, M., & Zhang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1574736 · Cited by 3
HOT mutation screening in human glioblastomas
Krell, D., Mulholland, P. J., Stebbing, J., Tomlinson, I. P. M., & Bardella, C. (2015) · Future Science OA · doi:10.4155/fso.15.20 · Cited by 2
Chemical Compounds Targeting DNA Methylation and Hydroxymethylation
Belle, R., Kawamura, A., & Arimondo, P. B. (2019) · Topics in medicinal chemistry · doi:10.1007/7355_2019_76 · Cited by 2
Insight into Structure-Activity Relationship of New Compounds for Breast Cancer Treatment
Li, L., & Zhang, Q. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266253686230921054429 · Cited by 2
Zaburzenia metabolizmu i funkcji enzymów metabolicznych a proces nowotworzenia
Sarnowska, E. A., Leszczynski, M., Macech-Klicka, E., Stachowiak, M., & SIEDLECKI, J. A. (2016) · Nowotwory Journal of Oncology · doi:10.5603/njo.2016.0024 · Cited by 3
Networks and Consortia for Epigenetic Drug Discovery
Weisenberger, D. J., & Brown, P. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802208-5.00006-0 · Cited by 2
Cytogenetic and Molecular Genetic Prognostic Factors of Acute Myeloid Leukemia
Misyurin, A. V. (2017) · Clinical oncohematology · doi:10.21320/2500-2139-2017-10-2-227-234 · Cited by 2
Maksoud, S. A., El‐Gamal, R. A. E., Pessar, S. A., Salem, D. D. E., Abdelsamee, H. F., & Agamy, H. S. (2019) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-019-0012-7 · Cited by 2
Wu, R. Y., Xie, X., Wei, Y., Jang, Z. X., Chen, D. D., Sun, H., Wan, D., Liu, Y., & Sun, L. (2021) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2021.01.008 · Cited by 2
Farina, P., Scotté, F., Villa, C., Baussart, B., & Stefano, A. L. D. (2018) · Springer eBooks · doi:10.1007/978-3-319-70253-7_7 · Cited by 2
Yang, J., Gupta, E., Horton, J. R., Blumenthal, R., Zhang, X., & Cheng, X. (2022) · DNA repair · doi:10.1016/j.dnarep.2022.103306 · Cited by 2
Acute Myeloid Leukemia Genomics: Impact on Care and Remaining Challenges
Eisfeld, A., & Mardis, E. R. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvad171 · Cited by 2
Yang, L., Pusch, S., Jennings, V., Ma, T., Zhu, Q., Xu, Y., von Deimling, A., & Zha, X. (2018) · Letters in Drug Design & Discovery · doi:10.2174/1570180815666180808094432 · Cited by 2
The return of quiescence metabolites
Coller, H. A. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00640-x · Cited by 2
Bilyy, R. O. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1660726 · Cited by 1
The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment
Zheng, S., Tong, Y., Yang, L., Chen, J., & Tan, Y. (2024) · Annals of Hematology · doi:10.1007/s00277-024-06050-x · Cited by 1
Huang, F., Tian, T., Wu, Y., Che, J., Yang, H., & Dong, X. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666201130102724 · Cited by 1
Li, S., & Yin, C. C. (2017) · Molecular pathology library · doi:10.1007/978-3-319-62146-3_4 · Cited by 1
Dowdy, T., & Larion, M. (2026) · Methods · doi:10.1016/j.ymeth.2026.08.005 · Cited by 1
Bouchard, M., McAllister, A., Bourlett, N. S., Hoyt, C., Calcul, L., & Walstrom, K. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178238 · Cited by 1
Molecular Markers for Risk Stratification in Adult Acute Myeloid Leukemia with Normal Cytogenetics
Fuchs, O. (2011) · InTech eBooks · doi:10.5772/19844 · Cited by 1
Targeted Therapy of IDH1-Mutated Tumors
Clark, O., & Grommes, C. (2016) · Springer eBooks · doi:10.1007/978-3-319-49864-5_10 · Cited by 1
Liu, Y., Li, N., Zhang, R., Sun, Y., Xu, C., Wang, Y., Xiong, J., & Chen, Q. (2019) · Glioma · doi:10.4103/glioma.glioma_46_18 · Cited by 1
Kurtović-Kozarić, A., Islamagić, E., Ašić, A., Mehinovic-Cavcic, L., Bešić, L., Sahinbegovic, H., Komic, H., Kurtovic, S., & Burazerović, L. (2021) · Acta Medica Academica · doi:10.5644/ama2006-124.334 · Cited by 1
Acquisition of IDH2 mutations in relapsed/refractory AML is associated with worse patient outcomes
Song, A., Altabbakh, O., Sallman, D. A., Padron, E., Talati, C., & Hussaini, M. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13698 · Cited by 1
Wahl, D. R., & Venneti, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-61401-4_6 · Cited by 1
Stem Cell Theory and Inflammation‐Related Cancer
Tanno, T., & Matsui, W. H. (2014) · Wiley eBooks · doi:10.1002/9781118826621.ch2 · Cited by 1
Mecucci, C., Battista, V. D., & Nofrini, V. (2016) · Wiley eBooks · doi:10.1002/9781118527948.ch1 · Cited by 1
Liu, A. M., Wang, W., & Luk, J. M. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-456-2_9
Prognostic and biological implications of epigenetic changes in leukemia
Deneberg, S. (2011) · Figshare
Willander, K. (2014) · Linköping University Electronic Press eBooks · doi:10.3384/diss.diva-104951
Dong-feng, C. (2013) · Lund University Publications (Lund University)
Studies on Genetic Aberrations in Acute Myeloid Leukemia
Abbas, S. (2011) · EUR Research Repository (Erasmus University Rotterdam)
Prognostic markers in pediatric leukemia and mechanisms of KRAS induced leukemogenesis
Staffas, A. (2013) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Znaczenie mutacji genów modulujących zmiany epigenetyczne w ostrej białaczce szpikowej
Zajac, M., & Giannopoulos, K. (2013) · Acta Haematologica Polonica · doi:10.1016/j.achaem.2013.11.001
Lou, K.-J. (2013) · Science-Business eXchange · doi:10.1038/scibx.2013.205
Walton, A. H. (2013) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg)
Malignant Glioma: Isocitrate Dehydrogenases 1 and 2 Mutations
Reitman, Z. J., & Yan, H. (2011) · Springer eBooks · doi:10.1007/978-94-007-0618-7_7
Challen, G. A., & Trowbridge, J. J. (2014) · Epigenetics and human health · doi:10.1007/978-3-642-45198-0_8
Otto Warburg's contributions to current concepts of cancer metabolism
Butenandt, A. (2011)
Genetic prognostic factors in acute myeloid leukemia
Erdei, A., Vellai, T., Andrikovics, H., & Váradi, A. (2014)
Preface to the column "Metabolism of Childhood Cancer".
Rakheja, D. (2015) · PubMed Central · doi:10.3978/j.issn.2224-4336.2015.02.02
Role of SIRT6 in Metabolic Reprogramming During Colorectal Carcinoma
Sebastián, C. (2014) · Defense Technical Information Center (DTIC) · doi:10.21236/ada614181
Pathogenesis and Mutations of Myeloproliferative Neoplasms: An Overview
Ipek, Y.-H., Fehmi, H., & Sargın, D. (2015) · Journal of Advances in Medicine and Medical Research · doi:10.9734/bjmmr/2015/17689
Energy metabolism pathway related genes and adaptive evolution of tumor cells
Liu, J., & Kong, Q. (2013) · Zoological Research · doi:10.3724/sp.j.1141.2012.06557
JAK2 and myeloproliferative neoplasms
Levine, R. L. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139046947.077
Markers for Diagnosis, Prognosis, and Therapy of Acute Myeloid Leukemia
Fuchs, O. (2013) · CRC Press eBooks · doi:10.1201/b16389-34
The molecular basis of acute myeloid leukemia
Rice, K. L., Buzzai, M., Altman, J. K., & Licht, J. D. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139046947.070
Acidúrias D-2-hidroxiglutárica e L-2-hidroxiglutárica: uma revisão da literatura
Rodrigues, D. G. B., & Vargas, C. R. (2016) · Clinical & Biomedical Research · doi:10.4322/2357-9730.61060
Balduf, H., Pepe, A., & Kirchmaier, A. L. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-6743-8_5
The Role of Cbx Proteins in Human Benign and Malignant Hematopoiesis
Jung, J., Schepers, H., Lazare, S., Buisman, S. C., Weersing, E., Dethmers-Ausema, B., Klauke, K., Bystrykh, L., & de Haan, G. (2016) · Blood · doi:10.1182/blood.v128.22.2651.2651
Recent Advances for Targeted Therapies in Glioblastoma
Youssef, M. N., Mandel, J. J., Chowdhary, S. A., & Kesari, S. (2017) · Current cancer research · doi:10.1007/978-3-319-56820-1_4
Targeted Quantification of Amino Acid Biomarkers Using LC‐MS
Jones, B. R., Biondolillo, R. F., & Buckholz, J. E. (2017) · Wiley eBooks · doi:10.1002/9781119413073.ch13
Functional alteration of canine isocitrate dehydrogenase 2 (IDH2) via an R174K mutation
Kawakami, S., Ochiai, K., Kato, Y., Michishita, M., Hirama, H., Obara, R., Azakami, D., Watanabe, M., & Omi, T. (2017) · Journal of Veterinary Medical Science · doi:10.1292/jvms.17-0362
The critical role of cysteine import and metabolism in pancreatic cancer
Badgley, M. A. (2017) · doi:10.7916/d8db8dhx
Mitochondria Remodeling in Cancer
Dornfeld, K. J., & Skildum, A. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-73344-9_9
Leki wpływające na mechanizmy epigenetyczne w ostrej białaczce szpikowej
Wiśniewski, K., & Góra‐Tybor, J. (2018) · Hematologia · doi:10.5603/hem.2018.0014
Zaburzenia mechanizmów epigenetycznych w ostrej białaczce szpikowej
Wiśniewski, K., Białopiotrowicz, E., & Góra‐Tybor, J. (2018) · Hematologia · doi:10.5603/hem.2018.0012
Functions of nuclear receptors in cancer metabolism
와이라구, 페. (2014) · YUHSpace (Yonsei University Medical Library)
Sirtuin signaling in hematologic malignancies
Denu, R. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822467-0.00012-7
Wang, B. Z. J. (2020) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/145566
Metabolic Deregulations in Acute Myeloid Leukemia
Mossuz, P., Chevalier, S., & Mondet, J. (2021) · Vide Leaf, Hyderabad eBooks · doi:10.37247/imcac.1.2021.3
Villarreal, B., & Nadilly, Y. (2021) · Figshare
Xu, M., Gao, S., Zeng, Y., Gao, A., Gao, L., Xu, L., Zhou, Y., Gao, J., Ye, Q., & Li, J. X. (2021) · Chinese Journal of Organic Chemistry · doi:10.6023/cjoc202010045
Grimwade, D. J., Knapper, S., & Mrózek, K. (2016) · Springer eBooks · doi:10.1007/978-3-319-19674-9_40
Der diagnostische Stellenwert der Isocitrat-Dehydrogenase-Mutationen beim Chondrosarkom
Juratli, T. A. (2022) · Osteologie/Osteology · doi:10.1055/a-1725-2083
Christopeit, M., Tischer, J., Bornhäuser, M., Uharek, L., Pfrepper, C., Behre, G., Niederwieser, D. W., Kroger, N., Rösler, W., Klein, S., et al. (2015) · Annals of Hematology · doi:10.1007/s00277-014-2297-4
Choate, K. A. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.726744181.793558674
Shayanfar, N., Zare‐Mirzaie, A., Mohammadpour, M., Jafari, E., Mehrtash, A., Emtiazi, N., & Tajik, F. (2022) · Research Square · doi:10.21203/rs.3.rs-1629748/v1
Bose, C. K., Basu, N., & Basu, M. (2021) · Onkologie · doi:10.36290/xon.2020.097
Chen, S., Yan, X., Zhou, G., & Zhu, C. H. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm011.pub2
Mutant IDH1 attenuates hepatic lipogenesis through PTEN dependent pathway
Zhao, Q. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.11.041
Ο ρόλος των μαστοκυττάρων στα μυελοδυσπλαστικά σύνδρομα
Καρράς, Γ. (2022) · doi:10.12681/eadd/52837
Wang, X., Bao, X., Zhang, J., Song, B., Li, M. Y., Xie, J., Shen, H., Wu, D., & Qiu, H. (2022) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2022.08.014
Liu, A. C. H., Cathelin, S., Yang, Y., Dai, D. L., Ayyathan, D. M., Hosseini, M., Minden, M. D., Tierens, A. M., & Chan, S. M. (2023) · doi:10.1158/0008-5472.c.6514302.v1
Self-citationLiu, A. C. H., Cathelin, S., Yang, Y., Dai, D. L., Ayyathan, D. M., Hosseini, M., Minden, M. D., Tierens, A. M., & Chan, S. M. (2023) · doi:10.1158/0008-5472.22433115.v1
Self-citationResearch Progress in the Relationship and Role of IDH1/2 Gene Mutation and Acute My-eloid Leukemia
戚, 栋. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1361289
The application of small molecule drug in clinical trial
Ding, Y., & xue, M. (2023) · Theoretical and Natural Science · doi:10.54254/2753-8818/23/20231031
Potential Correlation between Gene Mutations and Metabolic Changes in Acute Myeloid Leukemia
Jiang, A., Hou, Z., Yu, B., Wang, N., & Zhang, B. (2024) · The Natural Products Journal · doi:10.2174/0122103155277735231122105519
Dumont, S., & Scotté, F. (2023) · Springer eBooks · doi:10.1007/978-3-030-93702-7_7-1
Metadata
- Authors
- Gross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S. M., Dang, L., Fantin, V. R., & Mak, T. W.
- Affiliations
- Agios Pharmaceuticals Incorporated, Cambridge, MA 02139 1
- University Health Network (CA)
- Agios Pharmaceuticals (United States) (US)
- Corresponding author
- Fantin, Valeria R.
- Mak, Tak W.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2010-02-08
- Volume
- 207
- Issue
- 2
- Pages
- 339-344
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2822606
- OpenAlex
- W2159731673
- Cited by
- 736
- References
- 23
- Citations by year
- 2026: 10 · 2025: 19 · 2024: 34 · 2023: 35 · 2022: 29 · 2021: 55 · 2020: 40 · 2019: 36 · 2018: 45 · 2017: 51 · 2016: 61 · 2015: 44 · 2014: 49 · 2013: 61 · 2012: 61
- FWCI
- 45.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Leukemia and Lymphoma Society
- Agios Pharmaceuticals
- Terry Fox Foundation
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- 2-hydroxyglutarate, IDH mutation, acute myeloid leukemia, alpha-ketoglutarate, NADPH-dependent reduction, gain-of-function mutations, cancer metabolism, metabolic biomarkers
- MeSH terms
- Catalysis, Glutarates, Humans, Isocitrate Dehydrogenase, Ketoglutaric Acids, Mutation, NADP, Recombinant Proteins, Leukemia, Myeloid, Acute
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
